According to Brean Murray Carret, Incyte INCY price target is increased to $25 from $23.
Brean Murray Carret said that, due to the solid Phase 3 details and clarity of the anemia effect, it is increasing the target price to $25.
Incyte closed yesterday at $16.90.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsBiotechnologyBrean Murray Carret & CompanyHealth CareIncyte Corp.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
